Elutia Announces FDA Clearance of EluPro®: The First Antibiotic …
WEBJun 17, 2024 · EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market. EluPro also granted clearance for ...
Elutia Announces FDA Clearance of EluPro™: The First Antibiotic …
WEBJun 17, 2024 · EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market. EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea.
Elutia Announces First Patient Implant of EluPro™, the World’s …
WEBSILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA).
Elutia Announces New Peer Reviewed Publication Highlighting the ...
WEB4 days ago · EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting ...
Elutia Announces First Patient Implant of EluPro™, the
WEBSep 5, 2024 · EluPro is designed to prevent post-operative complications in patients with cardiac implantable devices such as pacemakers and internal defibrillators.
Elutia Announces First Patient Implant of EluPro™, the World’s …
WEBSILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the...
Elutia Announces New Peer Reviewed Publication Highlighting the ...
WEB3 days ago · EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model. SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting ...
Elutia Announces FDA Clearance of EluPro®: The First
WEBJun 17, 2024 · EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market
Elutia Announces FDA Clearance of EluPro: The First Antibiotic
WEBJune 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting BioEnvelope, EluPro (referred to as CanGaroo during development), has received clearance from the U.S. Food and Drug Administration (FDA).
Elutia Announces First Patient Implant of EluPro™, the World’s …
WEBSILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro ®, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA).
- Some results have been removed